ARID3A

Across TCGA pan-cancer cohorts, ARID3A mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ARID3A data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ARID3A mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ARID3A expression acts as an unfavorable survival marker, although some lineages such as LSCC and PDAC show a favorable association.

CCRCC, LSCC, and PDAC are the cancer types where ARID3A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Quartile	All	0.104	0.989	.010	30	view →
LSCC	OS	Quartile	All	0.987	0.683	.002	17	view →
PDAC	DFS	Tertile	All	0.564	0.316	.023	9	view →
COAD	DFS	Median	III,IV	0.852	1.000	.039	6	view →
GBM	OS	Median	All	0.286	0.555	.013	6	view →
HNSC	DFS	Quartile	IV	0.649	0.893	.040	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ARID3A–CCRCC (OS)

Open the CCRCC breakdown →